RBC Capital Reiterates Outperform on Surgery Partners, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix has reiterated an Outperform rating on Surgery Partners (NASDAQ:SGRY) and maintained a $49 price target.
February 29, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Ben Hendrix reiterated an Outperform rating on Surgery Partners and maintained a $49 price target.
The reiteration of an Outperform rating and maintenance of a $49 price target by a reputable analyst like Ben Hendrix from RBC Capital is likely to instill confidence among investors and could positively influence Surgery Partners' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100